Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Kymera Therapeutics (KYMR) EBITDA Margin: 2019-2025

Historic EBITDA Margin for Kymera Therapeutics (KYMR) over the last 6 years, with Sep 2025 value amounting to -2,928.84%.

  • Kymera Therapeutics' EBITDA Margin fell 136623.00% to -2,928.84% in Q3 2025 from the same period last year, while for Sep 2025 it was 124,181.51%, marking a year-over-year increase of 12436777.00%. This contributed to the annual value of -7,251.32% for FY2024, which is 706992.00% down from last year.
  • Kymera Therapeutics' EBITDA Margin amounted to -2,928.84% in Q3 2025, which was down 340.65% from -664.67% recorded in Q2 2025.
  • In the past 5 years, Kymera Therapeutics' EBITDA Margin registered a high of 202.77% during Q4 2024, and its lowest value of -2,928.84% during Q3 2025.
  • For the 3-year period, Kymera Therapeutics' EBITDA Margin averaged around -696.61%, with its median value being -412.18% (2023).
  • As far as peak fluctuations go, Kymera Therapeutics' EBITDA Margin surged by 29,812bps in 2021, and later tumbled by 136,623bps in 2025.
  • Kymera Therapeutics' EBITDA Margin (Quarterly) stood at -225.30% in 2021, then skyrocketed by 1,524bps to -210.06% in 2022, then surged by 18,401bps to -26.04% in 2023, then surged by 22,881bps to 202.77% in 2024, then slumped by 136,623bps to -2,928.84% in 2025.
  • Its last three reported values are -2,928.84% in Q3 2025, -664.67% for Q2 2025, and -290.29% during Q1 2025.